New study examines belantamab combos for myeloma relapse
NCT ID NCT07637526
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone) works in real-world, compassionate-use settings. The goal is to gather information on patient characteristics, treatment patterns, and outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin combined with bortezomib and dexamethasone, or with pomalidomide and dexamethasone
What this could lead to
If successful, this study could provide real-world evidence on how well these drug combinations work for multiple myeloma that has returned after initial treatment.
What could go wrong
This is a small, retrospective observational study, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients. There is also a risk of side effects from the drugs, such as eye problems or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••